Search Results

There are 31670 results for: content related to: Use of QT-prolonging medications in US emergency departments, 1995–2009

  1. High prevalence of risk factors in elderly patients using drugs associated with acquired torsades de pointes chronically in Colombia

    British Journal of Clinical Pharmacology

    Volume 82, Issue 2, August 2016, Pages: 504–511, Paula Andrea Moreno-Gutiérrez, Andrés Gaviria-Mendoza, Mauricio Montoya Cañón and Jorge Enrique Machado-Alba

    Version of Record online : 21 MAY 2016, DOI: 10.1111/bcp.12969

  2. Prevalence and determinants of QT interval prolongation in medical inpatients

    Internal Medicine Journal

    Volume 42, Issue 8, August 2012, Pages: 933–940, M. Pasquier, O. Pantet, O. Hugli, E. Pruvot, T. Buclin, G. Waeber and D. Aujesky

    Version of Record online : 21 AUG 2012, DOI: 10.1111/j.1445-5994.2011.02447.x

  3. Are ECG monitoring recommendations before prescription of QT-prolonging drugs applied in daily practice? The example of haloperidol

    Pharmacoepidemiology and Drug Safety

    Volume 24, Issue 7, July 2015, Pages: 701–708, Miriam Jacoba Warnier, Frans Hendrik Rutten, Patrick Cyriel Souverein, Anthonius de Boer, Arno Wilhelmus Hoes and Marie Louise De Bruin

    Version of Record online : 27 MAY 2015, DOI: 10.1002/pds.3792

  4. Frequency of high-risk use of QT-prolonging medications

    Pharmacoepidemiology and Drug Safety

    Volume 15, Issue 6, June 2006, Pages: 361–368, Nancy M. Allen LaPointe, Lesley H. Curtis, K. Arnold Chan, Judith M. Kramer, Jennifer Elston Lafata, Jerry H. Gurwitz, Marsha A. Raebel and Richard Platt

    Version of Record online : 22 SEP 2005, DOI: 10.1002/pds.1155

  5. The Cost-Effectiveness of Drug Regulation: The Example of Thorough QT/QTc Studies

    Clinical Pharmacology & Therapeutics

    Volume 91, Issue 2, February 2012, Pages: 281–288, J C Bouvy, M A Koopmanschap, R R Shah and H Schellekens

    Version of Record online : 28 DEC 2011, DOI: 10.1038/clpt.2011.224

  6. You have free access to this content
    Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice

    British Journal of Clinical Pharmacology

    Volume 76, Issue 1, July 2013, Pages: 48–57, Geoffrey K. Isbister and Colin B. Page

    Version of Record online : 20 JUN 2013, DOI: 10.1111/bcp.12040

  7. You have free access to this content
    Non-antiarrhythmic drugs prolonging the QT interval:considerable use in seven countries

    British Journal of Clinical Pharmacology

    Volume 54, Issue 2, August 2002, Pages: 171–177, Fabrizio De Ponti, Elisabetta Poluzzi, Alberto Vaccheri, Ulf Bergman, Lars Bjerrum, John Ferguson, Kerry J. Frenz, Peter McManus, Ingrid Schubert, Gisbert Selke, Georgia Terzis-Vaslamatzis and Nicola Montanaro

    Version of Record online : 4 SEP 2002, DOI: 10.1046/j.1365-2125.2002.01617.x

  8. You have free access to this content
    Abstracts

    Pharmacoepidemiology and Drug Safety

    Volume 24, Issue S1, September 2015, Pages: 1–587,

    Version of Record online : 25 SEP 2015, DOI: 10.1002/pds.3838

  9. Effects of KATP openers on the QT prolongation induced by HERG-blocking drugs in guinea-pigs

    Journal of Pharmacy and Pharmacology

    Volume 62, Issue 7, July 2010, Pages: 924–930, Lara Testai, Violetta Cecchetti, Stefano Sabatini, Alma Martelli, Maria Cristina Breschi and Vincenzo Calderone

    Version of Record online : 29 JUN 2010, DOI: 10.1211/jpp.62.07.0014

  10. Pharmacoepidemiology of QT-interval prolonging drug administration in critically ill patients

    Pharmacoepidemiology and Drug Safety

    Volume 17, Issue 10, October 2008, Pages: 971–981, Bradley D. Freeman, David J. Dixon, Craig M. Coopersmith, Barbara A. Zehnbauer and Timothy G. Buchman

    Version of Record online : 11 AUG 2008, DOI: 10.1002/pds.1637

  11. You have free access to this content
    Common candidate gene variants are associated with QT interval duration in the general population

    Journal of Internal Medicine

    Volume 265, Issue 4, April 2009, Pages: 448–458, A. Marjamaa, C. Newton-Cheh, K. Porthan, A. Reunanen, P. Lahermo, H. Väänänen, A. Jula, H. Karanko, H. Swan, L. Toivonen, M. S. Nieminen, M. Viitasalo, L. Peltonen, L. Oikarinen, A. Palotie, K. Kontula and V. Salomaa

    Version of Record online : 27 OCT 2008, DOI: 10.1111/j.1365-2796.2008.02026.x

  12. You have free access to this content
    Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period

    British Journal of Clinical Pharmacology

    Volume 67, Issue 1, January 2009, Pages: 88–98, Emanuel Raschi, Elisabetta Poluzzi, Chiara Zuliani, Arno Muller, Herman Goossens and Fabrizio De Ponti

    Version of Record online : 15 OCT 2008, DOI: 10.1111/j.1365-2125.2008.03319.x

  13. QT interval prolongation: prevalence, risk factors and pharmacovigilance data among methadone-treated patients in France

    Fundamental & Clinical Pharmacology

    Volume 25, Issue 4, August 2011, Pages: 503–510, Aurélie Perrin-Terrin, Atul Pathak and Maryse Lapeyre-Mestre

    Version of Record online : 6 SEP 2010, DOI: 10.1111/j.1472-8206.2010.00871.x

  14. Results From the IQ-CSRC Prospective Study Support Replacement of the Thorough QT Study by QT Assessment in the Early Clinical Phase

    Clinical Pharmacology & Therapeutics

    Volume 97, Issue 4, April 2015, Pages: 326–335, B Darpo, C Benson, C Dota, G Ferber, C Garnett, CL Green, V Jarugula, L Johannesen, J Keirns, K Krudys, J Liu, C Ortemann-Renon, S Riley, N Sarapa, B Smith, RR Stoltz, M Zhou and N Stockbridge

    Version of Record online : 16 MAR 2015, DOI: 10.1002/cpt.60

  15. Evaluation and Management of Cardiac Safety Using the Electrocardiogram in Oncology Clinical Trials: Focus on Cardiac Repolarization (QTc Interval)

    Clinical Pharmacology & Therapeutics

    Volume 87, Issue 2, February 2010, Pages: 166–174, J Morganroth, R R Shah and J W Scott

    Version of Record online : 9 DEC 2009, DOI: 10.1038/clpt.2009.214

  16. A Novel Method for Patient-Specific QTc—Modeling QT-RR Hysteresis

    Annals of Noninvasive Electrocardiology

    Volume 16, Issue 1, January 2011, Pages: 3–12, David M. Hadley, Victor F. Froelicher and Paul J. Wang

    Version of Record online : 20 JAN 2011, DOI: 10.1111/j.1542-474X.2010.00401.x

  17. A Pharmacokinetic-pharmacodynamic Model for the Quantitative Prediction of Dofetilide Clinical QT Prolongation from Human Ether-a-go-go-related Gene Current Inhibition Data

    Clinical Pharmacology & Therapeutics

    Volume 77, Issue 6, June 2005, Pages: 572–582, Daniël M. Jonker, Leslie A. Kenna, Derek Leishman, Rob Wallis, Peter A. Milligan and E. Niclas Jonsson

    Version of Record online : 9 JUN 2005, DOI: 10.1016/j.clpt.2005.02.004

  18. Clinical Relevance and Management of Drug-Related QT Interval Prolongation

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 23, Issue 7, July 2003, Pages: 881–908, Dr. Michael A. Crouch, Dr. Lynn Limon and Dr. Angela T. Cassano

    Version of Record online : 16 JAN 2012, DOI: 10.1592/phco.23.7.881.32730

  19. You have free access to this content
    A new mechanism preventing proarrhythmia in chronic heart failure: rapid phase-III repolarization explains the low proarrhythmic potential of amiodarone in contrast to sotalol in a model of pacing-induced heart failure

    European Journal of Heart Failure

    Volume 13, Issue 10, October 2011, Pages: 1060–1069, Gerrit Frommeyer, Peter Milberg, Patricia Witte, Jörg Stypmann, Matthias Koopmann, Martin Lücke, Nani Osada, Günter Breithardt, Michael Fehr and Lars Eckardt

    Version of Record online : 18 FEB 2014, DOI: 10.1093/eurjhf/hfr107

  20. Abstracts of the 26th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 19–22 August 2010, Brighton, UK

    Pharmacoepidemiology and Drug Safety

    Volume 19, Issue S1, August 2010, Pages: S1–S347,

    Version of Record online : 24 AUG 2010, DOI: 10.1002/pds.2019